$XLO
Xilio Therapeutics Inc

2021 Q4 Form 10-K Financial Statement

#000155837022002552 Filed on March 01, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.204M $23.86M $2.928M
YoY Change 180.19% 123.94%
% of Gross Profit
Research & Development $11.35M $51.19M $17.67M
YoY Change -35.76% 16.57%
% of Gross Profit
Depreciation & Amortization $394.0K $1.499M $657.0K
YoY Change -40.03% 40.75%
% of Gross Profit
Operating Expenses $19.56M $75.04M $20.60M
YoY Change -5.04% 37.54%
Operating Profit -$75.04M
YoY Change 37.54%
Interest Expense -$100.0K -$600.0K -$200.0K
YoY Change -50.0% 0.0%
% of Operating Profit
Other Income/Expense, Net -$45.00K -$756.0K $23.00K
YoY Change -295.65% 15.24%
Pretax Income -$19.70M -$75.80M -$20.77M
YoY Change -5.16% 37.27%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$19.70M -$75.80M -$20.77M
YoY Change -5.16% 37.27%
Net Earnings / Revenue
Basic Earnings Per Share -$13.52
Diluted Earnings Per Share -$738.8K -$13.52 -$779.0K
COMMON SHARES
Basic Shares Outstanding 27.47M 5.606M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $198.1M $198.1M
YoY Change 929.49%
Cash & Equivalents $198.1M $198.1M $19.24M
Short-Term Investments
Other Short-Term Assets $4.464M $4.464M $44.00K
YoY Change 10045.45% 230.18%
Inventory
Prepaid Expenses $1.308M
Receivables
Other Receivables
Total Short-Term Assets $202.5M $202.5M $20.59M
YoY Change 883.57% 883.57%
LONG-TERM ASSETS
Property, Plant & Equipment $7.620M $13.90M $7.367M
YoY Change 3.43% 1.64%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $393.0K $1.643M $500.0K
YoY Change -21.4% -19.89%
Total Long-Term Assets $15.54M $15.54M $15.73M
YoY Change -1.17% -1.17%
TOTAL ASSETS
Total Short-Term Assets $202.5M $202.5M $20.59M
Total Long-Term Assets $15.54M $15.54M $15.73M
Total Assets $218.1M $218.1M $36.32M
YoY Change 500.44% 500.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.144M $3.144M $5.444M
YoY Change -42.25% -42.25%
Accrued Expenses $8.751M $9.552M $13.73M
YoY Change -36.27% -33.18%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $82.00K
YoY Change -96.6%
Total Short-Term Liabilities $12.78M $12.78M $22.16M
YoY Change -42.32% -42.32%
LONG-TERM LIABILITIES
Long-Term Debt $9.628M $9.746M
YoY Change 28.25%
Other Long-Term Liabilities $118.0K $10.11M $1.127M
YoY Change -89.53% -14.69%
Total Long-Term Liabilities $118.0K $19.85M $1.127M
YoY Change -89.53% 2.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.78M $12.78M $22.16M
Total Long-Term Liabilities $118.0K $19.85M $1.127M
Total Liabilities $32.63M $32.63M $41.60M
YoY Change -21.56% -21.56%
SHAREHOLDERS EQUITY
Retained Earnings -$160.9M -$85.09M
YoY Change 89.09%
Common Stock $3.000K $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $185.4M $185.4M -$83.29M
YoY Change
Total Liabilities & Shareholders Equity $218.1M $218.1M $36.32M
YoY Change 500.44% 500.44%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$19.70M -$75.80M -$20.77M
YoY Change -5.16% 37.27%
Depreciation, Depletion And Amortization $394.0K $1.499M $657.0K
YoY Change -40.03% 40.75%
Cash From Operating Activities -$17.16M -$80.75M -$23.17M
YoY Change -25.92% 123.74%
INVESTING ACTIVITIES
Capital Expenditures -$378.0K $1.100M -$682.0K
YoY Change -44.57% -49.73%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$378.0K -$1.100M -$682.0K
YoY Change -44.57% -49.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $116.4M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 115.8M 260.7M 60.00K
YoY Change 192943.33% 2499.14%
NET CHANGE
Cash From Operating Activities -17.16M -80.75M -23.17M
Cash From Investing Activities -378.0K -1.100M -682.0K
Cash From Financing Activities 115.8M 260.7M 60.00K
Net Change In Cash 98.29M 178.8M -23.79M
YoY Change -513.17% -732.98%
FREE CASH FLOW
Cash From Operating Activities -$17.16M -$80.75M -$23.17M
Capital Expenditures -$378.0K $1.100M -$682.0K
Free Cash Flow -$16.78M -$81.85M -$22.48M
YoY Change -25.35% 113.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
523786
CY2021 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
5606308
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2021Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001840233
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2021Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
66788528
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-75800000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55219000
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-13.52
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-105.42
CY2021Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1053
CY2020Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2020Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent
CY2020Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-40925
CY2021 dei Entity Registrant Name
EntityRegistrantName
Xilio Therapeutics, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1623397
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
CY2021 dei City Area Code
CityAreaCode
617
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
118000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1127000
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
491000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
481000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
321000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
178000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8751000
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
828 Winter Street,
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10908000
CY2021 dei Local Phone Number
LocalPhoneNumber
430-4680
CY2021 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2021 dei Trading Symbol
TradingSymbol
XLO
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
0
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27468950
CY2021 dei Auditor Firm
AuditorFirmId
42
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
Boston, Massachusetts
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
198053000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19238000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4464000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1352000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
202517000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
20590000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1553000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1551000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
7620000
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
7367000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5977000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6309000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
393000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
500000
CY2021Q4 us-gaap Assets
Assets
218060000
CY2020Q4 us-gaap Assets
Assets
36317000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3144000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5444000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8751000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13732000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
801000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
564000
CY2020Q4 us-gaap Notes Payable Current
NotesPayableCurrent
2333000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
82000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
82000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12778000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22155000
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9628000
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
7412000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10107000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27468950
CY2021Q4 us-gaap Liabilities
Liabilities
32631000
CY2020Q4 us-gaap Liabilities
Liabilities
41602000
CY2020 xlo Noncash Interest Expense
NoncashInterestExpense
39000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
133602056
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
66788528
CY2021Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
80250000
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
78002000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27358375
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
126000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
973898
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
689929
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
346312000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1799000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160886000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85086000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
185429000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-83287000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
218060000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
36317000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
51188000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43910000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23856000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10653000
CY2021 us-gaap Operating Expenses
OperatingExpenses
75044000
CY2020 us-gaap Operating Expenses
OperatingExpenses
54563000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-75044000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-54563000
CY2021 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
756000
CY2020 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
656000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-756000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-656000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-75800000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-55219000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-13.52
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-105.42
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5606308
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
523786
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-29523000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
159000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1296000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4958000
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
13547000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-55219000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-83287000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-83287000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
222888000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1065000
CY2021 xlo Noncash Interest Expense
NoncashInterestExpense
173000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
116359000
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
28000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
283000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4958000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-75800000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
185429000
CY2021 us-gaap Profit Loss
ProfitLoss
-75800000
CY2020 us-gaap Profit Loss
ProfitLoss
-55219000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1499000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
1296000
CY2021 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-19000
CY2021 xlo Fair Value Adjustments Of Warrants And Derivative Liabilities
FairValueAdjustmentsOfWarrantsAndDerivativeLiabilities
203000
CY2020 xlo Fair Value Adjustments Of Warrants And Derivative Liabilities
FairValueAdjustmentsOfWarrantsAndDerivativeLiabilities
126000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3136000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2282000
CY2021 xlo Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-332000
CY2020 xlo Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-299000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2818000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2926000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-5617000
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
11510000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-564000
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-415000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-80751000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36091000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1100000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2188000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1100000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2188000
CY2021 us-gaap Repayments Of Debt
RepaymentsOfDebt
1000000
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
975000
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
85000
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
99000
CY2021 xlo Payment For Success Fees Financing Activities
PaymentForSuccessFeesFinancingActivities
750000
CY2020 xlo Proceeds From Issuance Of Preferred Units
ProceedsFromIssuanceOfPreferredUnits
9969000
CY2021 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
144886000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
116359000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
283000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
159000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
260668000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10029000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
178817000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-28250000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20789000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49039000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
199606000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20789000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
492000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
536000
CY2021 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
222888000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
539000
CY2021 xlo Derivative Liability Recognized
DerivativeLiabilityRecognized
250000
CY2021 xlo Conversion Of Warrants Into Equity
ConversionOfWarrantsIntoEquity
28000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
39000
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
423000
CY2020 xlo Tenant Improvements Funded By Landlord
TenantImprovementsFundedByLandlord
2827000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
198100000
CY2021 us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
false
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in accordance with GAAP requires management to make estimates and judgments that may affect the reported amounts of assets and liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the related reporting of expenses during the reporting period. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these consolidated financial statements. Factors that may affect estimates include expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. Significant estimates of accounting reflected in these consolidated financial statements include, but are not limited to, estimates related to accrued expenses, contingent amounts payable to third parties upon the consummation of specified transactions, including an initial public offering, the valuation of equity-based compensation, including incentive units, stock options and restricted common stock, useful life of long-lived assets and income taxes. Actual results could differ from those estimates.</p>
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
198053000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19238000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
1553000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
1551000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
199606000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20789000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk and Significant Suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company holds all cash and cash equivalents at accredited financial institutions. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. As of December 31, 2021 and 2020, certain of the Company’s primary operating accounts significantly exceeded the FDIC limits. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is dependent on a third-party manufacturer to supply material and manufacturing process development services for its product candidates and related research and development activities. These research and development programs and activities could be adversely affected by a significant interruption in the supply of such products and services which could have a material adverse effect on the Company’s business, financial position and results of operations.</p>
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2021Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
374000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
325000
CY2020 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
126000
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
825000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
453000
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
1250000
CY2021 xlo Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Conversion
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityConversion
28000
CY2021 xlo Purchase Commitment Notice Period Of Cancellation
PurchaseCommitmentNoticePeriodOfCancellation
P90D
CY2019Q3 xlo Lessee Operating Lease Area Leased
LesseeOperatingLeaseAreaLeased
27830
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10332000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8727000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2712000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1360000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7620000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7367000
CY2021 us-gaap Depreciation
Depreciation
1400000
CY2020 us-gaap Depreciation
Depreciation
1100000
CY2021Q4 xlo Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
2794000
CY2020Q4 xlo Accrued External Research And Development Current
AccruedExternalResearchAndDevelopmentCurrent
11060000
CY2021Q4 xlo Accrued Personnel Expenses Current
AccruedPersonnelExpensesCurrent
5145000
CY2020Q4 xlo Accrued Personnel Expenses Current
AccruedPersonnelExpensesCurrent
2013000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13732000
CY2019Q3 xlo Lessee Operating Lease Extended Lease Term
LesseeOperatingLeaseExtendedLeaseTerm
P5Y
CY2019Q3 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
true
CY2019Q3 xlo Lessee Operating Lease Maximum Tenant Improvements Reimbursed
LesseeOperatingLeaseMaximumTenantImprovementsReimbursed
4900000
CY2019Q3 xlo Lessee Operating Lease Reduction In Future Minimum Lease Payments
LesseeOperatingLeaseReductionInFutureMinimumLeasePayments
4900000
CY2019 xlo Lessee Operating Lease Tenant Improvement Reimbursement Received
LesseeOperatingLeaseTenantImprovementReimbursementReceived
2000000.0
CY2020 xlo Lessee Operating Lease Tenant Improvement Reimbursement Received
LesseeOperatingLeaseTenantImprovementReimbursementReceived
2900000
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1225000
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
1225000
CY2021 xlo Operating Lease Cost Including Variable Cost
OperatingLeaseCostIncludingVariableCost
1225000
CY2020 xlo Operating Lease Cost Including Variable Cost
OperatingLeaseCostIncludingVariableCost
1225000
CY2021 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
85000
CY2020 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
35000
CY2021 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
16000
CY2020 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
8000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5977000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6309000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
801000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
564000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10107000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10908000
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
303000
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
388000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
82000
CY2020Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
82000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
118000
CY2020Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
187000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1392000
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y2M1D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y2M1D
CY2021Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M12D
CY2020Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y8M12D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2021Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.069
CY2020Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.069
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
1343000
CY2021 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
85000
CY2020 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
99000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1634000
CY2021Q4 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
85000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1683000
CY2021Q4 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
85000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1733000
CY2021Q4 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
49000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1785000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1839000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
6361000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15035000
CY2021Q4 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
219000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4127000
CY2021Q4 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
19000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
10908000
CY2021Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
200000
CY2021Q4 us-gaap Common Unit Outstanding
CommonUnitOutstanding
0
CY2020Q4 us-gaap Preferred Units Outstanding
PreferredUnitsOutstanding
0
CY2021Q4 us-gaap Preferred Units Outstanding
PreferredUnitsOutstanding
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q4 xlo Number Of Classes Of Units
NumberOfClassesOfUnits
2
CY2020Q4 us-gaap Common Unit Outstanding
CommonUnitOutstanding
0
CY2020Q2 xlo Common Units Conversion Ratio
CommonUnitsConversionRatio
1
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
126000000
CY2020 xlo Temporary Equity Convertible Minimum Gross Proceeds From Sale Of Common Stock
TemporaryEquityConvertibleMinimumGrossProceedsFromSaleOfCommonStock
50000000
CY2020Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Conversion Of Convertible Preferred Stock Outstanding
CommonStockCapitalSharesReservedForFutureIssuanceConversionOfConvertiblePreferredStockOutstanding
7030359
CY2021Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Conversion Of Convertible Preferred Stock Issuable Upon Exercise Of Warrant
CommonStockCapitalSharesReservedForFutureIssuanceConversionOfConvertiblePreferredStockIssuableUponExerciseOfWarrant
2631
CY2020Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Conversion Of Convertible Preferred Stock Issuable Upon Exercise Of Warrant
CommonStockCapitalSharesReservedForFutureIssuanceConversionOfConvertiblePreferredStockIssuableUponExerciseOfWarrant
2631
CY2021Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Exercise Of Outstanding Stock Options
CommonStockCapitalSharesReservedForFutureIssuanceExerciseOfOutstandingStockOptions
4088456
CY2020Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Exercise Of Outstanding Stock Options
CommonStockCapitalSharesReservedForFutureIssuanceExerciseOfOutstandingStockOptions
810358
CY2021Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Future Stock Based Compensation Awards
CommonStockCapitalSharesReservedForFutureIssuanceFutureStockBasedCompensationAwards
2349875
CY2020Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Future Stock Based Compensation Awards
CommonStockCapitalSharesReservedForFutureIssuanceFutureStockBasedCompensationAwards
151769
CY2021Q4 xlo Common Stock Capital Shares Reserved For Future Issuance Employee Stock Purchase Plan
CommonStockCapitalSharesReservedForFutureIssuanceEmployeeStockPurchasePlan
292031
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6732993
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
7995117
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1296000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4958000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
810358
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.51
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y6M7D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3786967
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.93
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
47900
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.90
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
460969
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.22
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4088456
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.59
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y1M17D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
30291000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
717562
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.22
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y29D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
7019000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4088456
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
8.59
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y1M17D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
30291000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
500000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8127317
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4201662
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.067
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.069
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.005
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.004
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.003
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.017
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.017
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.286
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.292
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
31387000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
16376000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
8910000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
4400000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3873000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2101000
CY2021Q4 xlo Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
2980000
CY2020Q4 xlo Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
3134000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
340000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
765000
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
2061000
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
1912000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
733000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
105000
CY2021Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1883000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
46745000
CY2020Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
1944000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
50284000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
28793000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
25064000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3539000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3729000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021Q4 xlo Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
1633000
CY2020Q4 xlo Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
1724000
CY2021Q4 xlo Deferred Tax Liabilities Debt Discount
DeferredTaxLiabilitiesDebtDiscount
23000
CY2020Q4 xlo Deferred Tax Liabilities Debt Discount
DeferredTaxLiabilitiesDebtDiscount
61000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3539000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3729000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
21700000

Files In Submission

Name View Source Status
0001558370-22-002552-index-headers.html Edgar Link pending
0001558370-22-002552-index.html Edgar Link pending
0001558370-22-002552.txt Edgar Link pending
0001558370-22-002552-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xlo-20211231.xsd Edgar Link pending
xlo-20211231x10k.htm Edgar Link pending
xlo-20211231x10k001.jpg Edgar Link pending
xlo-20211231x10k002.jpg Edgar Link pending
xlo-20211231x10k003.jpg Edgar Link pending
xlo-20211231x10k004.jpg Edgar Link pending
xlo-20211231x10k005.jpg Edgar Link pending
xlo-20211231x10k006.jpg Edgar Link pending
xlo-20211231x10k007.jpg Edgar Link pending
xlo-20211231x10k008.jpg Edgar Link pending
xlo-20211231x10k009.jpg Edgar Link pending
xlo-20211231x10k010.jpg Edgar Link pending
xlo-20211231x10k011.jpg Edgar Link pending
xlo-20211231x10k012.jpg Edgar Link pending
xlo-20211231x10k013.jpg Edgar Link pending
xlo-20211231x10k014.jpg Edgar Link pending
xlo-20211231x10k015.jpg Edgar Link pending
xlo-20211231x10k016.jpg Edgar Link pending
xlo-20211231x10k017.jpg Edgar Link pending
xlo-20211231x10k018.jpg Edgar Link pending
xlo-20211231x10k019.jpg Edgar Link pending
xlo-20211231x10k020.jpg Edgar Link pending
xlo-20211231x10k021.jpg Edgar Link pending
xlo-20211231x10k022.jpg Edgar Link pending
xlo-20211231x10k023.jpg Edgar Link pending
xlo-20211231x10k024.jpg Edgar Link pending
xlo-20211231x10k025.jpg Edgar Link pending
xlo-20211231x10k026.jpg Edgar Link pending
xlo-20211231x10k027.jpg Edgar Link pending
xlo-20211231x10k_htm.xml Edgar Link completed
xlo-20211231xex10d20.htm Edgar Link pending
xlo-20211231xex23d1.htm Edgar Link pending
xlo-20211231xex31d1.htm Edgar Link pending
xlo-20211231xex31d2.htm Edgar Link pending
xlo-20211231xex32d1.htm Edgar Link pending
xlo-20211231xex4d3.htm Edgar Link pending
xlo-20211231_cal.xml Edgar Link unprocessable
xlo-20211231_def.xml Edgar Link unprocessable
xlo-20211231_lab.xml Edgar Link unprocessable
xlo-20211231_pre.xml Edgar Link unprocessable